MCF Advisors LLC Raises Holdings in Johnson & Johnson $JNJ

Posted by Lauren Steadman on Jun 6th, 2026

MCF Advisors LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 21.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,969 shares of the company’s stock after buying an additional 3,309 shares during the quarter. MCF Advisors LLC’s holdings in Johnson & Johnson were worth $3,926,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. First Command Advisory Services Inc. increased its holdings in Johnson & Johnson by 8.2% during the fourth quarter. First Command Advisory Services Inc. now owns 14,419 shares of the company’s stock valued at $2,984,000 after buying an additional 1,091 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its holdings in Johnson & Johnson by 10.0% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 452,586 shares of the company’s stock valued at $93,663,000 after buying an additional 41,073 shares during the period. Patron Partners LLC grew its holdings in Johnson & Johnson by 1.7% in the fourth quarter. Patron Partners LLC now owns 10,359 shares of the company’s stock worth $2,144,000 after purchasing an additional 178 shares during the last quarter. Formulate Financial LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $202,000. Finally, Pinebridge Investments LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $50,197,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Jim Cramer highlighted Johnson & Johnson’s lack of major patent expirations and pointed to its billion-dollar drugs and growing businesses as reasons to own the stock. Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Positive Sentiment: ASCO 2026 updates underscored Johnson & Johnson’s expanding specialty-drug pipeline, with encouraging data in autoimmunity, oncology, and myeloma that could support longer-term revenue growth. ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story
Positive Sentiment: Separate market coverage noted Johnson & Johnson has been outperforming the broader market recently, reinforcing investor confidence in the defensive healthcare name. Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
Neutral Sentiment: Newsweek named Johnson & Johnson among the world’s greenest companies for 2026, which is supportive for ESG-focused investors but unlikely to move the stock on its own. Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026
Neutral Sentiment: Analysts highlighted ongoing headwinds, including Stelara erosion, China MedTech pressure, and talc litigation, though J&J is still targeting $100 billion in revenue and faster growth in 2026. Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

Johnson & Johnson Trading Up 2.0%

NYSE:JNJ opened at $232.81 on Friday. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The firm has a fifty day simple moving average of $231.98 and a 200-day simple moving average of $225.96. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $560.42 billion, a P/E ratio of 26.91, a PEG ratio of 2.24 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the firm posted $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. Johnson & Johnson’s payout ratio is presently 61.97%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on JNJ shares. Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 15th. Citigroup lifted their price target on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a report on Wednesday, May 13th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

View Our Latest Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.